Tecfidera’s Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches
Over the next six months, Tecfidera's patient share among DMT-treated RR-MS patients is anticipated to increase significantly to 16 percent. In fact, despite being the third oral DMT to reach the MS market, patient share for Tecfidera exceeds that for the first two oral DMTs for MS—Sanofi/Genzyme’s Aubagio (1 percent) and Novartis’s Gilenya (1 percent)—at the same stage of their respective launches. Current physician trial rate for Tecfidera (65 percent) beats that for Aubagio (33 percent) and Gilenya (53 percent).
Salt-Heavy Diets Can Lead to Autoimmune Diseases
Men's Journal
These ailments, which include multiple sclerosis, type 1 diabetes, inflammatory bowel disease, and psoriasis, result from an immune system gone haywire that ...
Prescription-Drug Coupons — No Such Thing as a Free Lunch
Visit
nearly any official website for a brand-name drug available in the
United States and, mixed in with links to prescribing and safety
information, you'll find links to drug “coupons,” including
copayment-assistance programs and monthly savings cards. Most offers are
variations on “Why pay more? With the [drug] savings card, you can get
[drug] for only $18 per prescription if eligible” or “Get a free
30-capsule trial of [drug] with your doctor's prescription and ask your
doctor if [drug] is right for you.” Why do manufacturers offer drug
coupons? Are they good for patients in the long run? Are they even
legal?Endogenous retroviruses and multiple sclerosis--new pieces to the puzzle
7thSpace Interactive (press release)
The possibility that retroviruses play a role in multiple sclerosis (MS) has long been considered; accumulating findings suggest this to be most likely in the form of ...
How Will the Obamacare Out-of-Pocket Cap Delay Affect MS Patients?
Healthline
For people with multiple sclerosis (MS) who must often pay high co-payments for health services and prescription drugs, this news comes as a crushing blow.
Opexa Therapeutics Inc awarded 50th patent for T-cell immunotherapy platform for multiple sclerosis
MENAFN.COM
Aug 28, 2013 (Menafn - M2 EQUITYBITES via COMTEX) --Biotechnology company Opexa Therapeutics Inc (nasdaqcm:OPXA) reported on Tuesday the receipt ...
Atos Tests Branded 'Farcical' After Finding Multiple Sclerosis ...
Huffington Post UK
The study looked at people with cystic fibrosis, multiple sclerosis, Parkinson's or rheumatoid arthritis who applied for Employment Support Allowance between ...
Big Sunfest cheques thrill MS societies
Canada.com
Both the Cowichan Exhibition Society and the Cowichan Valley chapter of the Multiple Sclerosis Society were the happy recipients of big cheques Thursday, ..
Non-myeloablative autologous haematopoietic stem cell transplantation
expands regulatory cells and depletes IL-17 producing mucosal-associated
invariant T cells in multiple sclerosis
Magnetic resonance monitoring of lesion evolution in multiple sclerosis
Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner
Community: Sept. 21 event to benefit MS program
Corvallis Gazette Times
The runs will benefit Oregon State's Multiple Sclerosis Exercise Program, which helps people with multiple sclerosis. Participants in the program receive free ...
PLEASE SHARE THIS WITH YOUR FELLOW DOCTORS, NURSES & PATIENTS BY CLICKING ON THE TINY ENVELOPE BELOW:
